Bengay was developed in France by Dr. Jules Bengué (French pronunciation:[ʒylbɛ̃ɡe]) and brought to North America in 1898. The name Bengué was Anglicized and commercialized to Ben-Gay (later Bengay). It was originally produced by Pfizer Consumer Healthcare, which was acquired by Johnson & Johnson. The product is advised to be used topically for adults and children 12 years of age and older, and no more than 3 to 4 times daily.[2] The manufacturer recommends storing it between 20 and 25 °C (68 and 77 °F).[2]
According to a study published by MIT Technology Review, the exact mechanism of its efficacy is not known. However, evidence indicates that it activates the neuron receptor TRPM8, which appears to keep minor pain signals in the brain from communicating with the spine.[3]
Methyl salicylate can also be toxic when excessively large doses, many multiples of the recommended amount, are administered;[6][7] however it's an extreme rarity.[7]
In October 2007 in the United States, a teenage athlete overdosed and died from overexposure to methyl salicylate,[6][7] having "more than six times the safe amount of the ingredient in her body."[6]
Active ingredients
Active ingredients vary by product version, including: